Association of the PIG3 promoter polymorphism with invasive bladder cancer in a Japanese population

Japanese Journal of Clinical Oncology

Volumn 36, Issue 2, 2006, Pages 116-120

  Ito, Masaaki ^a   Nishiyama, Hiroyuki ^a   Watanabe, Jun ^a   Kawanishi, Hiroaki ^a   Takahashi, Takeshi ^a   Kamoto, Toshiyuki ^a   Habuchi, Tomonori ^b   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; PIG3; VNTRs

Indexed keywords

GENOMIC DNA; PROTEIN P53;

ADULT; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; PROMOTER REGION; RISK ASSESSMENT; VARIABLE NUMBER OF TANDEM REPEAT;

AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; MALE; MIDDLE AGED; MINISATELLITE REPEATS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 33645163853     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi225     Document Type: Article

References (26)

1. Foresman WH and Messing, EM. Bladder Cancer: Natural History, tumor markers, and early detection strategies. Semin Surg Oncol 1997;13:299-306.
2. Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitumori K, Itoh N, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89:724-30.
3. Miyanaga N, Ohtani M, Akaza H, Koiso K. Clinical statistical studies on bladder cancer in Japan. Nihon Rinsyo 1993;51:823-9.
4. Takagi Y, Takashi M, Koshikawa T, Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 2000;7:366-72.
5. Wagner U, Suess K, Luginbuhl T, Schmid U, Ackermann D, Zellwegener T. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999;188:44-50.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
7. Cordon-Cardo C, Dalbagani G, Saez GT, Oliva MR, Zhang ZF, Rosai J, et al. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-53.
8. Sarkis AS, Dalbagani G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-92.
9. Spruck CH, Ohnesit PF, Gonzares-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
10. Esrig D, Spruck CH, Nicols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
11. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura S, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993;53:3795-9.
12. el-Deiry MS, Harper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
13. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300-5.
14. Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet 2002;30:315-20.
15. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al. AJCC Cancer Staging Manual. 5th edn. Philadelphia: Lippincott-Raven 1997; 241-3.
16. The Japanese Urological Association and the Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer. 3rd edn. Tokyo: Kanahara-Shuppan 2001; 56-8.
17. Mostofi FK, Sobin L, Torloni H. Histological typing of urinary bladder tumors. In: International Histological Classification of Tumors, No. 10. Geneva: World Health Organization 1973; 15-34.
18. Watanabe J, Nishiyama H, Okubo K, Takahashi T, Toda Y, Habuchi T, et al. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 2004;63:989-93.
19. Gorgoulis VG, Liloglou T, Sigala F, Korkolis D, Yannoukakos D, Papalambros E, et al. Absence of association with cancer risk and low frequency of alterations at a p53 responsive PIG3 gene polymorphism in breast and lung carcinomas. Mut Res 2004;556:43-50.
20. Catherine AR, Somdatta S, Knut PJ, Melissa SB, Jairaj AP, David FJ. Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 2000;5:191-203.
21. Flatt PM, Polyak K, Tang LJ, Scatena CD, Westfall MD, Rubinstein JY, et al. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett 2000;156:63-72.
22. Venot C, Maratrat M, Dureutil C, Conseiller E, Bracco L, Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 1998;17:4668-79.
23. Chesis PL, Levin DE, Smith MT, Lars E, Ames BN. Mutagenicity of quinones: Pathways of metabolic activation and detoxification. Proc Natl Acad Sci USA 1984;81:1696-700.
24. Beyer RE, Segura-Aguliar J, Di Bernardo M, Cavazzoni R, Fato R, Fiorentini D, et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci USA 1996;93:2528-32.
25. Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. The reduction of α-tocopherolquinone by human NAD(P)H:qUinone oxidoreductase: The role of α-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol 1997;52:300-5.
26. Schulz WA, Kummeck A, Rosinger I, Eickelmann P, Neuhas C, Ebert T, et al. Increased frequency of a null allele for NAD(P)H: Quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997;7:235-9.